Research And Markets Research And Markets

Global Licensing Partnering Terms & Agreements in Pharma, Biotech & Diagnostics 2010-2016

  • ID: 2889861
  • May 2016
  • Region: Global
  • 2500 Pages
  • CurrentPartnering
1 of 4

The Global Licensing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2010- 2016 report provides comprehensive understanding and unprecedented access to the licensing deals and agreements entered into by the worlds leading life science companies.

This report provides details of the latest licensing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully up to date, the report provides details of licensing agreements from 2010 to 2016.

There has been a long standing willingness for parties to enter licensing deals. Such deals enable both parties to benefit from the upside of a big R&D win, whilst mitigating the risks of going it alone in the risky preclinical and clinical development stages.

Licensing is a specific type of partnering deal whereby the parties to the deal agree to commercialize a compound, product or technology.

Specifically, licensing is the granting of permission to use intellectual property rights, such as trademarks, patents, or technology, under defined conditions

There are several forms of licensing deal. Traditional licensing arrangement whereby an owner of intellectual property (the licensor) provides access to its technology to another company (the licensee) in return for READ MORE >

Note: Product cover images may vary from those shown
2 of 4

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in licensing deal making

2.1. Introduction
2.2. Definition of licensing deals
2.3. Success factors for licensing deals
2.4. When licensing can be useful
2.5. Attributes of licensing deals
2.6. Trends in licensing deals since 2010
2.6.1. Licensing deal making by year, 2010 to 2016
2.6.2. Licensing deal making by phase of development, 2010 to 2016
2.6.3. Licensing deal making by industry sector, 2010 to 2016
2.6.4. Licensing deal making by therapy area, 2010 to 2016
2.6.5. Licensing deal making by technology type, 2010 to 2016
2.6.6. Licensing deal making by most active company, 2010 to 2016
2.7. Option to license
2.8. Adding co-promotion to the mix
2.9. The future of licensing deals

Chapter 3 - Overview of licensing deal structure

3.1. Introduction
3.2. Pure versus multi-component licensing deals
3.3. Pure licensing agreement structure
3.3.1. Example licensing agreements
3.3.1.a. Case study 1: Ignyta - Nerviano Medical Sciences
3.3.1.b. Case study 2: Sanofi - Pozen
3.4. Licensing rights as part of a wider alliance agreement
3.4.1. Example licensing clauses
3.4.1.a. Case study 3: 4D Molecular Therapeutics - UniQure
3.4.1.b. Case study 4: Kyowa Hakko Kirin - Ultragenyx Pharmaceuticals
3.4.2. Example licensing option right clauses
3.4.2.a. Case study 5: Forest Laboratories - Trevena
3.4.2.b. Case study 6: Abbvie - Receptos

Chapter 4 - Leading licensing deals

4.1. Introduction
4.2. Top licensing deals by value

Chapter 5 - Top 50 most active licensing dealmakers

5.1. Introduction
5.2. Top 50 most active licensing dealmakers

Chapter 6 - Licensing deal term financials

6.1. Introduction
6.2. Licensing partnering headline values
6.3. Licensing deal upfront payments
6.4. Licensing deal milestone payments
6.5. Licensing royalty rates

Chapter 7 - Licensing contract directory 2010 - 2016

7.1. Introduction
7.2. Licensing deals with contracts 2010 to 2016


Appendix 1 - Licensing dealmaking by companies A-Z
Appendix 2 - Licensing dealmaking by industry sector
Appendix 3 - Licensing dealmaking by stage of development
Appendix 4 - Licensing dealmaking by therapy area
Appendix 5 - Licensing dealmaking by technology type


Table of Figures

Figure 1: Definition of licensing
Figure 2: Situations where licensing can prove useful
Figure 3: Key attributes of a licensing deal
Figure 4: Trends in licensing deal announcements, 2010 to 2016
Figure 5: Licensing deals signed at each phase of development, 2010 to 2016
Figure 6: Licensing deals by industry sector, 2010 to 2016
Figure 7: Licensing deals by therapy area, 2010 to 2016
Figure 8: Licensing deals by technology type, 2010 to 2016
Figure 9: Top 50 most active licensing dealmakers, 2010 to 2016
Figure 10: Licensing agreements - what should a contract include?
Figure 11: Components of the licensing deal structure
Figure 12: Top licensing deals by value 2010 to 2016
Figure 13: Most active licensing dealmakers 2010 to 2016
Figure 14: Licensing deals with a headline value
Figure 15: Licensing deals with an upfront value
Figure 16: Licensing deals with a milestone value
Figure 17: Licensing deals with a royalty rate value

Note: Product cover images may vary from those shown
3 of 4

Global Licensing Terms & Agreements in Pharma, Biotech & Diagnostics 2011-2015 provides the reader with the following key benefits:

- In-depth understanding of licensing partnering deal trends since 2011.
- Insight into the terms included in a licensing agreement, together with real world clause examples.
- Identify leading licensing deals by value since 2011.
- Identify the most active licensing dealmakers since 2011.
- Analysis of key deal financials including headline value, upfront, milestone payments and royalty rates.
- Full listing of licensing deals by company A-Z, deal value, phase of development, deal type, therapy and technology focus.
- Comprehensive access to over 3,500 licensing deals entered into by the world’s biopharma companies, together with contract documents if available.
- Detailed access to actual licensing contracts entered into by the leading fifty big pharma and big biotech companies.
- Understand the key deal terms companies have agreed in previous deals.
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown